Evidence map›Paper›PMID 41071949›Full record

ArticleBlood advances2026

Targeting macrophages prevents alloantibody-mediated platelet clearance in a murine model of transfusion refractoriness.

Gabriel Rojas-Jiménez, Catherine Angénieux, Fabienne Proamer, Anita Eckly, Blandine Maître

Abstract read
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Gabriel Rojas-JiménezUniversité de Strasbourg, Strasbourg, France.ORCID 0000-0003-3370-5894
Catherine AngénieuxUniversité de Strasbourg, Strasbourg, France.ORCID 0000-0002-0475-1165
Fabienne ProamerUniversité de Strasbourg, Strasbourg, France.
Anita EcklyUniversité de Strasbourg, Strasbourg, France.ORCID 0000-0001-9620-4961
Blandine MaîtreUniversité de Strasbourg, Strasbourg, France.ORCID 0000-0002-3264-7330

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractHLA class I-immunized patients can experience a serious complication known as platelet transfusion refractoriness (PTR). This issue becomes especially relevant in onco-hematology departments where platelet transfusions are at the heart of patient care. Although transfusion failure is evidenced by a rapid elimination of allogeneic platelets from the recipient's bloodstream, the mechanisms behind it remain poorly characterized. The aim of this study was to better define these mechanisms to improve therapy for PTR. Using a murine model of major histocompatibility complex class I incompatibility to mimic PTR, we first established that antibodies, but not natural killer or CD8 cells, mediated platelet clearance. However, blocking Fcγ receptors with intravenous immunoglobulin or a monoclonal antibody or complement depletion did not correct refractoriness in alloimmune mice. Therefore, we investigated other alternatives beyond antibody-dependent mechanisms. Flow cytometric and microscopic analysis showed that Kupffer cells in the liver and red pulp macrophages in the spleen phagocytose allogeneic platelets during PTR. Moreover, intravital microscopy revealed allogeneic platelets retained in close interaction with macrophages in the red pulp only in alloimmune animals. Splenectomy or Kupffer cell depletion with clodronate in alloimmune mice suggested the existence of compensatory elimination mechanisms in the liver and spleen. Therefore, the simultaneous removal of both macrophage populations was an effective strategy to abrogate PTR. Our study provides an insight into the mechanisms of platelet clearance in alloimmune pathologies and opens up new perspectives for therapeutic targets.

Indexed as

Blood PlateletsIsoantibodiesMacrophagesPlatelet TransfusionAnimalsDisease Models, AnimalHumansMiceIsoantibodies

Identifiers

PMID41071949
PMCPMC12828813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.